Aristotle Atlantic Partners, LLC Guardant Health, Inc. Transaction History

Aristotle Atlantic Partners, LLC

  • $3.42 Billion
  • Q3 2025

A detailed history of Aristotle Atlantic Partners, LLC transactions in Guardant Health, Inc. stock. As of the latest transaction made, Aristotle Atlantic Partners, LLC holds 923,734 shares of GH stock, worth $87.2 Million. This represents 1.69% of its overall portfolio holdings.

Number of Shares
923,734
Previous 931,956 0.88%
Holding current value
$87.2 Million
Previous $48.5 Million 19.0%
% of portfolio
1.69%
Previous 1.49%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
SELL
$40.98 - $67.42 $336,937 - $554,327
-8,222 Reduced 0.88%
923,734 $57.7 Million
Q2 2025

Aug 14, 2025
SELL
$37.05 - $52.04 $1.21 Million - $1.69 Million
-32,565 Reduced 3.38%
931,956 $48.5 Million
Q1 2025

May 15, 2025
BUY
$31.77 - $49.94 $3.57 Million - $5.62 Million
112,526 Added 13.21%
964,521 $41.1 Million
Q4 2024

Feb 14, 2025
SELL
$20.2 - $38.11 $838,562 - $1.58 Million
-41,513 Reduced 4.65%
851,995 $26 Million
Q3 2024

Nov 14, 2024
BUY
$22.3 - $36.29 $3.22 Million - $5.24 Million
144,311 Added 19.26%
893,508 $20.5 Million
Q2 2024

Aug 14, 2024
SELL
$16.07 - $31.84 $927,206 - $1.84 Million
-57,698 Reduced 7.15%
749,197 $21.6 Million
Q1 2024

May 15, 2024
SELL
$17.13 - $26.91 $514,756 - $808,645
-30,050 Reduced 3.59%
806,895 $16.6 Million
Q4 2023

Feb 14, 2024
BUY
$21.58 - $29.5 $61,481 - $84,045
2,849 Added 0.34%
836,945 $22.6 Million
Q3 2023

Nov 14, 2023
SELL
$25.8 - $39.97 $605,577 - $938,175
-23,472 Reduced 2.74%
834,096 $24.7 Million
Q2 2023

Aug 14, 2023
BUY
$20.94 - $38.01 $4.96 Million - $9.01 Million
237,074 Added 38.21%
857,568 $30.7 Million
Q1 2023

May 15, 2023
BUY
$22.92 - $33.76 $39,491 - $58,168
1,723 Added 0.28%
620,494 $14.5 Million
Q4 2022

Feb 14, 2023
BUY
$25.44 - $59.78 $6.05 Million - $14.2 Million
237,627 Added 62.35%
618,771 $16.8 Million
Q3 2022

Nov 14, 2022
BUY
$43.66 - $61.0 $7.51 Million - $10.5 Million
172,050 Added 82.28%
381,144 $20.5 Million
Q2 2022

Aug 15, 2022
BUY
$28.82 - $77.35 $112,225 - $301,200
3,894 Added 1.9%
209,094 $8.44 Million
Q1 2022

May 16, 2022
BUY
$48.25 - $100.49 $137,367 - $286,095
2,847 Added 1.41%
205,200 $13.6 Million
Q4 2021

Feb 14, 2022
BUY
$88.71 - $120.43 $658,494 - $893,951
7,423 Added 3.81%
202,353 $20.2 Million
Q3 2021

Nov 15, 2021
BUY
$98.77 - $132.17 $219,565 - $293,813
2,223 Added 1.15%
194,930 $24.4 Million
Q2 2021

Aug 16, 2021
BUY
$109.77 - $165.68 $201,867 - $304,685
1,839 Added 0.96%
192,707 $23.9 Million
Q1 2021

May 17, 2021
BUY
$127.04 - $179.1 $439,812 - $620,044
3,462 Added 1.85%
190,868 $29.1 Million
Q4 2020

Feb 16, 2021
BUY
$99.96 - $135.93 $274,790 - $373,671
2,749 Added 1.49%
187,406 $24.2 Million
Q3 2020

Nov 16, 2020
BUY
$80.32 - $111.8 $125,299 - $174,408
1,560 Added 0.85%
184,657 $20.6 Million
Q2 2020

Aug 14, 2020
BUY
$60.49 - $97.5 $2.17 Million - $3.5 Million
35,855 Added 24.35%
183,097 $14.9 Million
Q1 2020

May 14, 2020
BUY
$59.04 - $88.81 $239,584 - $360,390
4,058 Added 2.83%
147,242 $10.2 Million
Q4 2019

Feb 13, 2020
BUY
$59.49 - $82.78 $5.96 Million - $8.29 Million
100,167 Added 232.85%
143,184 $11.2 Million
Q3 2019

Nov 14, 2019
BUY
$62.59 - $110.3 $63,278 - $111,513
1,011 Added 2.41%
43,017 $2.75 Million
Q2 2019

Aug 13, 2019
BUY
$63.94 - $91.11 $118,352 - $168,644
1,851 Added 4.61%
42,006 $3.63 Million
Q1 2019

May 15, 2019
BUY
$34.3 - $97.98 $1.38 Million - $3.93 Million
40,155 New
40,155 $3.08 Million

Others Institutions Holding GH

# of Institutions
449
Shares Held
125M
Call Options Held
2.18M
Put Options Held
2.69M
View Full List

About Guardant Health, Inc.

GH Quotes by TradingView
  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $9.65B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Aristotle Atlantic Partners, LLC Portfolio

Follow Aristotle Atlantic Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aristotle Atlantic Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aristotle Atlantic Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email